Cambridge-based ReactWise, an AI-driven platform for chemical process optimization, has raised $3.4 million in pre-seed funding to accelerate pharmaceutical manufacturing. Backed by Y Combinator, Innovate U.K., and private investors, the company is pioneering an AI copilot that significantly speeds up drug production by optimizing chemical reactions 30 times faster than traditional methods.
Founded in July 2024 by Alexander Pomberger and Daniel Wigh, ReactWise automates chemical process development, reducing reliance on trial-and-error. Pharmaceutical companies can leverage its AI to predict optimal reaction conditions instantly, cutting process development time by up to 60%. With 12 ongoing pilot trials, including partnerships with Big Pharma, ReactWise aims to transform drug manufacturing and accelerate time-to-market for life-saving medications.
Featured image: Credit: ReactWise
